Some lipidized peptide-based drugs for treatment of diabetes or obesity have been introduced into the market, such as the insulin analog detemir, which employs myristic acid attached through an amide bound to insulin molecules (Havelund et al., 2004), and liraglutide, a palmitoylated agonist of glucagon-like peptide 1 (GLP-1) (Gault et al., 2011). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.